Management discusses the data presented at the recently-held 65th American Society of Hematology Annual Meeting on a conference call to be held on December 12 at 12 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RHHBY:
- New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
- Poseida presents efficacy, safety results from Phase 1 study of P-BCMA-ALLO1
- New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A
- Roche’s Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
- Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation